Continuing our commitment to invest in the future of Parkinson's research, NPF has announced two new awards to support promising young Parkinson's disease researchers: a fellowship for training neurologists in the field of movement disorders and a research grant to help young faculty to accelerate their scientific careers.
The Movement Disorder Center at UC San Diego Health System has been designated the 41st Center of Excellence in NPF's global network. This competitive designation is the highest recognition offered by NPF to a Parkinson’s specialty clinic and represents the consensus of leaders in the field that the multidisciplinary clinic at UC San Diego Health System is among the world’s leading centers for Parkinson’s research, outreach and care.
The U.S. Food and Drug Administration (FDA) has approved DUOPA™, developed by AbbVie Inc., as a treatment for people with advanced Parkinson's disease. DUOPA™ is a new approach to the delivery of carbidopa and levodopa for the treatment of the motor symptoms of Parkinson's disease; it is administered using a small, portable infusion pump that delivers carbidopa and levodopa directly into the small intestine.
Impax Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) approved RYTARY, an extended-release oral capsule formulation of carbidopa-levodopa, for the treatment of Parkinson's disease.